ERBB2 and neoplasm: Using the TCGA dataset, Wolfson and colleagues showed that patients carrying HER2-amplified tumours with high NCL expression levels had shorter overall and disease-free survivals than the ones carrying HER2-amplified tumours with low NCL expression levels [14].